| 351 | XGNExagen Inc. |
66,6 mln USD |
-30,0% |
2025 |
| 352 | ENTAEnanta Pharmaceuticals Inc |
65,3 mln USD |
-125,4% |
2025 |
| 353 | FBIOPFortress Biotech, Inc. |
63,3 mln USD |
10,8% |
2025 |
| 354 | NUVBNuvation Bio Inc. |
62,9 mln USD |
-325,3% |
2025 |
| 355 | TNGXTango Therapeutics, Inc. |
62,4 mln USD |
-162,9% |
2025 |
| 356 | DERMJourney Medical Corp |
61,9 mln USD |
-18,5% |
2025 |
| 357 | CSBRChampions Oncology, Inc. |
59,4 mln USD |
-2,0% |
2026 |
| 358 | APTAlpha Pro Tech Ltd |
59,1 mln USD |
6,0% |
2025 |
| 359 | LNSRLENSAR, Inc. |
58,4 mln USD |
-58,7% |
2025 |
| 360 | CVRXCVRx, Inc. |
56,7 mln USD |
-94,1% |
2025 |
| 361 | NKTRNektar Therapeutics |
55,2 mln USD |
-297,1% |
2025 |
| 362 | AGIOAgios Pharmaceuticals, Inc. |
54 mln USD |
-764,0% |
2025 |
| 363 | QTTBQ32 Bio Inc. |
53,7 mln USD |
55,5% |
2025 |
| 364 | IVVDInvivyd, Inc. |
53,4 mln USD |
-98,2% |
2025 |
| 365 | APYXApyx Medical Corp |
52,8 mln USD |
-21,2% |
2025 |
| 366 | PLXProtalix BioTherapeutics, Inc. |
52,7 mln USD |
-12,5% |
2025 |
| 367 | OCULOcular Therapeutix, Inc |
52 mln USD |
-511,9% |
2025 |
| 368 | CARLCarlsmed, Inc. |
50,5 mln USD |
-58,7% |
2025 |
| 369 | LXRXLexicon Pharmaceuticals, Inc. |
49,8 mln USD |
-101,1% |
2025 |
| 370 | GOSSGossamer Bio, Inc. |
48,5 mln USD |
-351,5% |
2025 |
| 371 | SIShoulder Innovations, Inc. |
47,3 mln USD |
-85,3% |
2025 |
| 372 | PTGXProtagonist Therapeutics, Inc |
46 mln USD |
-282,8% |
2025 |
| 373 | SEPNSepterna, Inc. |
46 mln USD |
-106,4% |
2025 |
| 374 | TLSITriSalus Life Sciences, Inc. |
45,2 mln USD |
-86,9% |
2025 |
| 375 | FENCFennec Pharmaceuticals Inc. |
44,6 mln USD |
-21,8% |
2025 |
| 376 | AQSTAquestive Therapeutics, Inc. |
44,5 mln USD |
-188,1% |
2025 |
| 377 | CPIXCumberland Pharmaceuticals Inc |
44,5 mln USD |
-6,4% |
2025 |
| 378 | SNWVSANUWAVE Health, Inc. |
44,1 mln USD |
26,8% |
2025 |
| 379 | XLOXilio Therapeutics, Inc. |
43,8 mln USD |
-80,1% |
2025 |
| 380 | WVEWave Life Sciences Ltd. |
42,7 mln USD |
-478,3% |
2025 |
| 381 | SSIISS Innovations International, Inc. |
42,5 mln USD |
-28,5% |
2025 |
| 382 | CHRSCoherus Oncology, Inc. |
42,2 mln USD |
398,4% |
2025 |
| 383 | KRMDKORU Medical Systems, Inc. |
41,1 mln USD |
-6,4% |
2025 |
| 384 | MYOMyomo, Inc. |
40,9 mln USD |
-38,1% |
2025 |
| 385 | EDITEditas Medicine, Inc. |
40,5 mln USD |
-395,0% |
2025 |
| 386 | TKNOAlpha Teknova, Inc. |
40,5 mln USD |
-42,6% |
2025 |
| 387 | VYGRVoyager Therapeutics, Inc. |
40,4 mln USD |
-296,5% |
2025 |
| 388 | KYMRKymera Therapeutics, Inc. |
39,2 mln USD |
-794,0% |
2025 |
| 389 | UTMDUtah Medical Products Inc |
38,5 mln USD |
29,3% |
2025 |
| 390 | BGMBGM Group Ltd. |
37,9 mln USD |
-52,6% |
2025 |
| 391 | CLPTClearPoint Neuro, Inc. |
37 mln USD |
-69,1% |
2025 |
| 392 | CCCCC4 Therapeutics, Inc. |
35,9 mln USD |
-292,1% |
2025 |
| 393 | VRCAVerrica Pharmaceuticals Inc. |
35,6 mln USD |
-50,3% |
2025 |
| 394 | SENSSenseonics Holdings, Inc. |
35,3 mln USD |
-196,0% |
2025 |
| 395 | XFORX4 Pharmaceuticals, Inc |
35,1 mln USD |
-225,6% |
2025 |
| 396 | BHSTBioharvest Sciences Inc. |
34,5 mln USD |
-32,3% |
2025 |
| 397 | DTILPrecision Biosciences Inc |
34,3 mln USD |
-133,4% |
2025 |
| 398 | OBIOOrchestra BioMed Holdings, Inc. |
33,5 mln USD |
-157,4% |
2025 |
| 399 | MXCTMaxcyte, Inc. |
33 mln USD |
-135,1% |
2025 |
| 400 | STXSStereotaxis, Inc. |
32,4 mln USD |
-66,8% |
2025 |